Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Repare Therapeutics ( (RPTX) ) has shared an announcement.
On January 16, 2026, Repare Therapeutics’ shareholders overwhelmingly approved XenoTherapeutics Inc. and Xeno Acquisition Corp., a non-profit biotechnology group, to acquire all outstanding Repare common shares through a statutory plan of arrangement, with 99.76% of votes cast in favor, including the vote excluding related parties under minority protection rules. At the same special meeting, investors also endorsed, on a non-binding basis, transaction-related executive compensation and, as a contingency if the acquisition does not close, approved resolutions for a potential voluntary liquidation and dissolution of the company and the appointment of KPMG LLP (or another nationally recognized firm) as liquidator, signaling strong shareholder support for either a sale or an orderly wind-down depending on the outcome of the deal process.
The most recent analyst rating on (RPTX) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.
Spark’s Take on RPTX Stock
According to Spark, TipRanks’ AI Analyst, RPTX is a Neutral.
The score is held back primarily by weak financial performance (deep losses and ongoing cash burn), partially offset by a strong balance sheet and positive corporate developments (asset sale boosting cash and early clinical updates). Technicals are constructive with a strong trend, but near-overbought signals and limited valuation support due to negative earnings temper the upside.
To see Spark’s full report on RPTX stock, click here.
More about Repare Therapeutics
Repare Therapeutics Inc. is a clinical-stage precision oncology company that uses a proprietary synthetic lethality approach to discover and develop highly targeted cancer therapies focused on genomic instability and DNA damage repair, with a pipeline that includes RP-1664, a Phase 1 PLK4 inhibitor. The company operates in the biopharmaceutical sector, targeting oncology markets with novel therapeutics designed to exploit specific genetic vulnerabilities in tumors.
Average Trading Volume: 1,000,783
Technical Sentiment Signal: Hold
Current Market Cap: $112.1M
For a thorough assessment of RPTX stock, go to TipRanks’ Stock Analysis page.
